|Articles|November 1, 2001

New Directions in the Treatment and Prevention of Deep Vein Thrombosis
Volume 7
Issue 17 Suppl

Participating Faculty

Download PDF: Participating Faculty

Articles in this issue

over 24 years ago

Article

Introduction

over 24 years ago

Article

Treatment of Deep Vein Thrombosis Using Low-Molecular-Weight Heparins

over 24 years ago

Article

Prophylaxis Strategies for Patients with Acute Venous Thromboembolism

over 24 years ago

Article

Economic Issues in the Treatment and Prevention of Deep Vein Thrombosis From a Managed Care Perspective

over 24 years ago

Article

The Use of Pharmacoeconomics in Formulary Development: Can This Improve the Way Deep Vein Thrombosis is Treated?

over 24 years ago

Article

Interview

over 24 years ago

Article

Continuing Medical Education Quiz

over 24 years ago

Article

Literature Review

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Participating Faculty

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

AHRQ Grant Freeze Halts Patient Safety Research Nationwide

FDA Advisory Panel Votes Against Approval of Deramiocel for DMD

MASLD, MASH Linked to Higher Mild Cognitive Impairment Risk, Lower Dementia Odds

Addressing Mental Health Challenges Among Black and Latino Boys